Compare Nebius Group NV (NBIS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs BIO-TECHNE Corp — how do they compare? Nebius Group NV trades at $219.7 (market cap $46.37B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Nebius Group NV is far larger — about 4.2× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.
| NBIS | TECH | |
|---|---|---|
Market Cap | $46.37B | $11.16B |
Sector | Technology | Health |
52-Week High | $286.69 | $72.12 |
52-Week Low | $50.40 | $43.31 |
Enterprise Value | $46.56B | $11.24B |
Dividend Yield | — | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
